Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-12-01 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
BLOCK LISTING INTERIM REVIEW
Foreign Filer Report
2021-12-01 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2021-12-01 English
Block listing Interim Review
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing Six Monthly Return' filed by AstraZeneca PLC via the London Stock Exchange's RNS (Regulatory News Service). This type of filing reports on the issuance of shares under specific employee share option schemes over a six-month period. It does not fit into specific categories like 'Share Issue' (which usually refers to new capital raises) or 'Transaction in Own Shares' (buybacks). As it is a standard regulatory disclosure regarding share schemes, it falls under the 'Regulatory Filings' (RNS) category.
2021-12-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and contains information mandated by the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. Specifically, it announces the total number of voting rights and the issued share capital as of a specific date (30 November 2021). This type of mandatory regulatory disclosure regarding capital structure and voting rights fits best under the category related to general regulatory announcements or specific shareholder/voting rights information. Since it is a routine disclosure about the total number of voting rights, it aligns closely with the scope of 'Declaration of Voting Results & Voting Rights Announcements' (DVA) or, more broadly, a standard regulatory filing. Given the content explicitly details the 'Voting rights and capital' denominator required by transparency rules, DVA is the most precise fit among the specific options, although RNS is also plausible if DVA is too narrow. However, DVA specifically covers voting rights announcements. The document is short and is a direct notification, not an announcement *about* a report, so RPA/RNS fallback is less preferred than the specific DVA category if applicable. DVA covers 'Official results from shareholder votes at any general meeting (AGM or EGM)'—while this isn't the *result* of a vote, it is the required denominator for voting rights calculations, making DVA the closest fit for a voting rights disclosure.
2021-12-01 English
LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA
Foreign Filer Report
2021-11-30 English
Lynparza granted FDA Priority Review for OlympiA
Regulatory Filings Classification · 100% confidence The document is a press release issued via RNS (RNS Number : 0051U) on November 30, 2021, announcing that the supplemental New Drug Application (sNDA) for Lynparza has been accepted and granted Priority Review by the US FDA. This is a specific corporate event announcement regarding regulatory progress, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). It is a regulatory update concerning a specific drug application status. Since it is a formal announcement distributed through a regulatory news service (RNS) detailing a specific regulatory event (FDA Priority Review acceptance), it fits best under the general 'Regulatory Filings' category (RNS) as it is not covered by more specific codes like DIV, CAP, or MANG. Although it contains detailed medical/scientific information, its primary function here is the announcement of the regulatory action itself.
2021-11-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.